Siamab Therapeutics: New funding, new name, new direction in cancer immunotherapy

Cambridge startup Siamab Therapeutics has changed up its direction, now developing monoclonal antibodies to hinder the progressive growth of tumors. The company just received another $2 million in funding, largely from angel investors, rounding out a $6 million Series B that began last year. On top of that, it just changed its name from Sialix to Siamab Therapeutics, representing the company’s […]